Table 1.

Summary of preclinical cancer models tested with oncolytic MYXV.

Type of Cancers	Animal Model	Tumor Establishment	MYXV Constructs and Delivery	Combination Therapy	Outcome (Ref)
Small cell lung cancer (SCLC)	C57BL/6 (p53lox/loxp p130lox2722/lox2722 RbloxP/loxP)	Intratracheal injection of adenovirus expressing Cre-recombinase	vMyx-M135KO, intranasal instillation	Virus alone and with cisplatin	Prolonged survival of mice when combined with cisplatin [22]
	NSG	Subcutaneous xenograft of human primary SCLC cells	Wild type (WT), intratumoral	none	Virus replication and extensive tumor necrosis [22]
	C57BL/6	Subcutaneous xenograft of mouse SCLC cells	WT, intratumoral	none	Virus replication, extensive tumor necrosis and CD45+ immune cell infiltration [22]
Ovarian cancer (OC)	C57BL/6	Murine OC cells in intraperitoneal cavity	WT and vMyx-M062RKO, intraperitoneal cavity	Virus alone and with cisplatin	Prolonged survival of mice when combined with cisplatin [23]
Glioblastoma (GBM)	C57BL/6J	Intracranial injection of murine BTICs	WT and vMyx-M11KO, intratumoral	Virus alone and with temozolomide	Prolonged survival of mice when combined with temozolomide [24]
Gallbladder cancer (GBC)	CD-1 nude	Subcutaneous xenograft of human GBC cells	WT, intratumoral	Virus alone and with Rapamycin or hyaluronan	Combination treatment with hyaluronan reduced tumor burden and prolonged survival [25]
Melanoma	C57BL/6 RAG-/-	Intracranial injection of mouse B16.SIY melanoma cells	WT, intratumoral	Virus alone, with rapamycin and activated T cells	Prolonged survival of mice when combined all the treatments [26]
	C57BL/6	Subcutaneous injection of B16F10 cells	WT and vMyx-IL-15, intratumoral injection	none	Prolonged survival of mice treated with vMyx-IL15 [27]
	C57BL/6 and C57BL/6 RAG-/-	Subcutaneous injection of B16F10 cells	WT, vMyx-IL-15 and vMyx-IL-15Rα-IL-15 intratumoral injection	none	Prolonged survival of mice with increased infiltration of NK and CD8+ T cells to the tumor bed [28]
Multiple myeloma (MM)	BALB/c	Intravenous injection of mouse MOPC315.BM cells	WT, delivery of virus with total bone marrow	none	Prolonged survival of mice [29]
	BALB/c	Intravenous injection of mouse MOPC315 cells	WT, systemic delivery	none	Prolonged survival of mice [30]
Embryonal rhabdomyosarcoma (ERMS)	NSG	Subcutaneous xenograft of human ERMS cells	WT and NRAS targeting CRISPR-Cas9 engineered MYXV, intratumoral injection	none	Reduced tumor volume and prolonged mice survival [31]